JP6943941B2 - Injectable and cosmetic compositions containing lemon balm extract as an active ingredient - Google Patents
Injectable and cosmetic compositions containing lemon balm extract as an active ingredient Download PDFInfo
- Publication number
- JP6943941B2 JP6943941B2 JP2019234300A JP2019234300A JP6943941B2 JP 6943941 B2 JP6943941 B2 JP 6943941B2 JP 2019234300 A JP2019234300 A JP 2019234300A JP 2019234300 A JP2019234300 A JP 2019234300A JP 6943941 B2 JP6943941 B2 JP 6943941B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- weight
- lemon balm
- active ingredient
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 47
- 244000062730 Melissa officinalis Species 0.000 title claims description 38
- 235000010654 Melissa officinalis Nutrition 0.000 title claims description 35
- 239000002537 cosmetic Substances 0.000 title claims description 34
- 239000004480 active ingredient Substances 0.000 title claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 235000009496 Juglans regia Nutrition 0.000 claims description 13
- 235000020234 walnut Nutrition 0.000 claims description 10
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 8
- AIPVRBGBHQDAPX-UHFFFAOYSA-N hydroxy(methyl)silane Chemical compound C[SiH2]O AIPVRBGBHQDAPX-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 claims description 7
- 229940100573 methylpropanediol Drugs 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 6
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 6
- 229950006790 adenosine phosphate Drugs 0.000 claims description 6
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- 240000007049 Juglans regia Species 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 4
- 229940045809 horse chestnut seed Drugs 0.000 claims description 3
- 241000254173 Coleoptera Species 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000007924 injection Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 208000035484 Cellulite Diseases 0.000 description 14
- 206010049752 Peau d'orange Diseases 0.000 description 14
- 230000036232 cellulite Effects 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000002366 lipolytic effect Effects 0.000 description 9
- 241000758789 Juglans Species 0.000 description 8
- 230000004130 lipolysis Effects 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000010181 horse chestnut Nutrition 0.000 description 6
- QGXLVXZRPRRCRP-IDIVVRGQSA-L Adenosine 5'-phosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O QGXLVXZRPRRCRP-IDIVVRGQSA-L 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007972 injectable composition Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229960001456 adenosine triphosphate Drugs 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229960003964 deoxycholic acid Drugs 0.000 description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000001926 lymphatic effect Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000157282 Aesculus Species 0.000 description 3
- 241000157280 Aesculus hippocastanum Species 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 244000196998 Pilea microphylla Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940089093 botox Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- MQSZRBPYXNEFHF-UHFFFAOYSA-N rhamnocitrin Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C=C1 MQSZRBPYXNEFHF-UHFFFAOYSA-N 0.000 description 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 210000000216 zygoma Anatomy 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- RJURRZFUWSRXDY-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1.CC(O)OC1=CC=CC=C1 RJURRZFUWSRXDY-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- NALUDDWNDBCDQS-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound C(C)C(O)(C(O)CO)CCCCCC.C(C)C(O)(C(O)CO)CCCCCC NALUDDWNDBCDQS-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N E-Sorbic acid Chemical compound C\C=C\C=C\C(O)=O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010068737 Facial asymmetry Diseases 0.000 description 1
- 206010061857 Fat necrosis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960003001 adenosine triphosphate disodium Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- BCMSQWPLFBUUKW-IXLPVNPSSA-M cefuzonam sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=CN=NS1 BCMSQWPLFBUUKW-IXLPVNPSSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000020721 horse chestnut extract Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- MGIYRDNGCNKGJU-UHFFFAOYSA-N isothiazolinone Chemical compound O=C1C=CSN1 MGIYRDNGCNKGJU-UHFFFAOYSA-N 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940082473 melissa officinalis leaf extract Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- PEFNSGRTCBGNAN-UHFFFAOYSA-N nephrocizin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical group 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- -1 triterpene acids Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
本発明は、レモンバーム抽出物を有効成分として含む注射剤及び化粧料組成物に関する。 The present invention relates to injections and cosmetic compositions containing lemon balm extract as an active ingredient.
一般的に、細長いVライン型の顔は誰もが好む顔型である。特に、最近では、まるまるとした顔から脱して、小さくて彫りの深い顔ラインを形成しようとする人々が多い傾向にある。 In general, an elongated V-line face is the face type that everyone likes. In particular, recently, there is a tendency for many people to break away from the round face and form a small, deeply carved face line.
脂肪吸引(lipoplasty)を目的としてホスファチジルコリン(Phosphatidylcholine、PPという)とデオキシコール酸(sodium deoxycholate)を利用した複合製剤注射剤が局所肥満に多く利用されてきた。 For the purpose of liposuction, a composite injection using phosphatidylcholine (PP) and deoxycholic acid (sodium deoxycholate) has been widely used for local obesity.
しかし、このようなホスファチジルコリンとデオキシコール酸を利用した複合製剤注射剤による脂肪壊死塊の発生により、ホスファチジルコリンを除いたデオキシコール酸の単独製剤を利用した脂肪分解組成物を開発しているが、デオキシコール酸の単独製剤を利用した脂肪分解組成物の場合、浮腫、紅斑、痛症、皮膚硬結などの副作用が頻繁に発生するという問題点がある。 However, due to the generation of fat necrosis due to the injection of a complex preparation using phosphatidylcholine and deoxycholic acid, a lipolytic composition using a single preparation of deoxycholic acid excluding phosphatidylcholine has been developed. In the case of a lipolytic composition using a single preparation of cholic acid, there is a problem that side effects such as edema, erythema, pain, and skin cirrhosis frequently occur.
一方、コスメシューティカル(Cosmeceutical)とは、化粧品(cosmetics)と製薬(pharmaceuticals)の合成語であり、薬用化粧品を意味する。検証された効能の医薬成分を化粧品につなぎ合わせた製品である。医者、薬剤師などの医療専門家が研究開発に参加した化粧品もコスメシューティカルに属する。既存の化粧品が皮膚管理のためのものであれば、コスメシューティカル製品は皮膚治療に焦点が合わせられている。 On the other hand, cosmetics is a synthetic word of cosmetics and pharmaceuticals, and means medicinal cosmetics. It is a product that combines pharmaceutical ingredients with verified efficacy into cosmetics. Cosmetics in which medical professionals such as doctors and pharmacists participated in research and development also belong to cosmetics. If the existing cosmetics are for skin care, cosmetic products are focused on skin treatment.
過度な皮下脂肪の除去及び皮膚弾力の増進に効果的なスリミング(slimming)及びアンチセルライト(anti−cellulite)化粧品に対する要求もたゆまず高まっている。 There is a constant growing demand for slimming and anti-cellulite cosmetics that are effective in removing excess subcutaneous fat and increasing skin elasticity.
本発明は、前述した従来技術の問題点を解決するためのものであって、注射だけで容易に顔を細長くする注射剤組成物を提供することを目的とする。 An object of the present invention is to solve the above-mentioned problems of the prior art, and an object of the present invention is to provide an injection composition that easily elongateds a face only by injection.
本発明は、皮膚に適用して直接的に脂肪細胞内の脂肪を分解し、セルライト除去効果を表すことができる化粧料組成物を提供することを目的とする。 An object of the present invention is to provide a cosmetic composition that can be applied to the skin to directly decompose fat in adipocytes and exhibit a cellulite removing effect.
本発明の実施例によると、レモンバーム抽出物を有効成分とする脂肪分解用注射剤組成物を提供する。 According to the examples of the present invention, there is provided an injection composition for lipolysis containing a lemon balm extract as an active ingredient.
本発明の実施例によると、レモンバーム抽出物、マロニエ(Aesculus Hippocastanum)抽出物、ヒバマタ(Fucus Vesiculosus)抽出物、クルミ(Juglans Regia)抽出物、ADP(Disodium Adenosine Phosphate)、Adenosine Triphosphate、Tyrosineを含む注射剤組成物を提供する。 According to the examples of the present invention, a lemon balm extract, a horse chestnut extract, a rockweed extract, a walnut wrack extract, a walnut (Juglans Regia) extract, an ADP (Disodium Adenosine Triphosphate) The agent composition is provided.
本発明の実施例によると、上記組成物を有効成分として含有する脂肪分解用注射剤組成物を提供する。 According to the examples of the present invention, there is provided an injection composition for lipolysis containing the above composition as an active ingredient.
本発明の第1実施例によると、塩化ナトリウム0.898重量%、プロピレングリコール0.11462重量%、フェノキシエタノール0.0468重量%、メチルプロパンジオール0.04重量%、レモンバーム抽出物0.01875重量%、チロシン0.00800重量%、セイヨウトチノキ種子抽出物0.00560重量%、クルミ抽出物0.00560重量%、エチルヘキシルグリセリン0.00520重量%、ヒバマタ抽出物0.00240重量%、メチルシラノールマンヌロン酸0.00180重量%、ソルビン酸0.00100重量%、アデノシンリン酸0.00024重量%、アデノシン三リン酸二ナトリウム0.00024重量%、及び残量の精製水を含むレモンバーム抽出物を有効成分とする注射剤組成物を提供する。 According to the first embodiment of the present invention, sodium chloride 0.898% by weight, propylene glycol 0.11462% by weight, phenoxyethanol 0.0468% by weight, methylpropanediol 0.04% by weight, lemon balm extract 0.01875% by weight. , Tyrosine 0.00800% by weight, Pseudomonas aeruginosa seed extract 0.00560% by weight, Walnut extract 0.00560% by weight, Ethylhexyl glycerin 0.00520% by weight, Hibamata extract 0.00240% by weight, Methylsilanol mannurone Active ingredient is lemon balm extract containing 0.00180% by weight of acid, 0.00100% by weight of sorbic acid, 0.00024% by weight of adenosine phosphate, 0.00024% by weight of disodium adenosine triphosphate, and the remaining amount of purified water. To provide an injectable composition.
本発明の第2実施例によると、精製水、塩化ナトリウム、レモンバーム抽出物、セイヨウトチノキ種子抽出物、クルミ抽出物、チロシン(Tyrosine)、ヒバマタ抽出物、アデノシンリン酸(Adenosine Phosphate)、アデノシン三リン酸二ナトリウム(DISODIUM ADENOSINE TRIPHOSPHATE)、メチルプロパンジオール(METHYLPROPANEDIOL)、メチルシラノールマンヌロン酸(METHYLSILANOL MANNURONATE)を含むレモンバーム抽出物を有効成分とする化粧料組成物を提供する。 According to the second embodiment of the present invention, purified water, sodium chloride, lemon balm extract, sardine seed extract, walnut extract, tyrosine, hibamata extract, adenosine phosphate, adenosine triphosphate. Provided is a cosmetic composition containing a lemon balm extract containing disodium acid (DISODIUM ADENOSINE TRIPHOSPHATE), methylpropanediol (METHYLPROPANEDIOL), and methylsilanol mannuronic acid (METHYLSILANOL MANNURONATE) as an active ingredient.
本発明の第3実施例によると、化粧料組成物において、
塩化ナトリウム0.898重量%、レモンバーム抽出物0.01875重量%、チロシン0.00800重量%、セイヨウトチノキ種子抽出物0.00560重量%、クルミ抽出物0.00560重量%、ヒバマタ抽出物0.00240重量%、アデノシンリン酸0.00024重量%、アデノシン三リン酸二ナトリウム0.00024重量%、メチルプロパンジオール0.04000重量%、メチルシラノールマンヌロン酸0.00180重量%及び残量の精製水を含み、
上記組成物は、超音波機器、高周波機器、エレクトロポレーション、または針のないインジェクトによって皮膚に適用されることを特徴とするレモンバーム抽出物を有効成分とする化粧料組成物を提供する。
According to the third embodiment of the present invention, in the cosmetic composition,
Sodium chloride 0.898% by weight, lemon balm extract 0.01875% by weight, tyrosine 0.00800% by weight, green beetle seed extract 0.00560% by weight, walnut extract 0.00560% by weight, hibamata extract 0.00240% by weight %% by weight, 0.00024% by weight of adenosine phosphate, 0.00024% by weight of disodium adenosine triphosphate, 0.04000% by weight of methylpropanediol, 0.00180% by weight of methylsilanol mannuronic acid, and purified water remaining. Including
The composition provides a cosmetic composition containing a lemon balm extract as an active ingredient, which is characterized by being applied to the skin by an ultrasonic device, a high frequency device, electroporation, or a needleless injection.
本発明によると、注射だけで容易に顔が細長くなる注射剤組成物を提供することができる。 According to the present invention, it is possible to provide an injection composition in which the face is easily elongated only by injection.
本発明によると、レモンバーム抽出物を有効成分として塗布される領域の脂肪を分解し、セルライトを除去する化粧料組成物を提供することができる。 According to the present invention, it is possible to provide a cosmetic composition in which the lemon balm extract is used as an active ingredient to decompose the fat in the area to be applied and remove cellulite.
以下、本発明の具体的な実施例を添付の図面を参照して詳しく説明する。 Hereinafter, specific examples of the present invention will be described in detail with reference to the accompanying drawings.
本発明の実施例によるレモンバーム抽出物を有効成分として含む脂肪分解組成物は、脂肪分解、リンパ循環、Vラインの顔、弾力のある顔のために注射剤で皮下に投薬されるか化粧料組成物として塗布されることができる。 The lipolytic composition containing the lemon balm extract according to the examples of the present invention as an active ingredient may be administered subcutaneously with an injection for lipolysis, lymphatic circulation, V-line face, elastic face or cosmetic composition. It can be applied as an object.
本発明の実施例による組成物は、上まぶた脂肪、目下脂肪、頬肉、頬骨、口元脂肪、顎ライン、二重顎などの部位に注射して、脂肪分解を通じて顔ラインを正すのに施術されることができる。個人の顔状態によって繊細な彫刻が可能な効果的な組成物である。浮腫の緩和、脂肪分解、リンパ循環の促進、アンチセルライトの作用をする。 The composition according to the embodiment of the present invention is injected into sites such as upper eyelid fat, current fat, cheek meat, cheekbone, mouth fat, chin line, and double chin to correct the facial line through lipolysis. Can be done. It is an effective composition that allows delicate engraving depending on the individual's facial condition. It works to relieve edema, lipolysis, promote lymphatic circulation, and anti-cellulite.
本発明の実施例による脂肪分解用注射剤組成物は、レモンバーム抽出物、マロニエ(Aesculus Hippocastanum)抽出物、ヒバマタ抽出物、クルミ抽出物、ADP(Disodium Adenosine Phosphate)、Adenosine Triphosphate、Tyrosineを含むことが好ましい。 The injectable composition for lipolysis according to the examples of the present invention may contain lemon balm extract, horse chestnut (Aesculus Hippocastanum) extract, hibamata extract, walnut extract, ADP (Disodium Adenosine Phosphate), and Adenosine Triphosphate. preferable.
本発明の第1実施例による脂肪分解注射剤組成物は、次の成分から構成されることが好ましい。 The lipolytic injection composition according to the first embodiment of the present invention is preferably composed of the following components.
レモンバーム(Melissa officinalis)は、シソ科(Labiatae)に属する植物として、多様な活性フラボノイド(シナロサイド(cynaroside)、コスモシン(cosmosin)、ラムノシトリン(rhamnocitrin)、イソクェルシトリン(isoquercitrin))、テルペン及びトリテルペン酸(triterpene acids:ウルソール酸(ursolic acid)及びオレアノール酸(oleanolic acid))を含有していると知られており(Herodez SS、Hadolin M、Skerget M、Knez Z Solvent extraction study of antioxidants from balm(Melissa officinalis L) leaves Food Chemistry 200;80:275−82)、精油、コーヒー酸及びロスマリン酸、モノテルペンとセスキテルペン、フェノール系物質及びタンニンなどの活性成分もレモンバームから分離抽出された。現在までレモンバーム抽出物の抗敗血症(Ulbricht C、Brendler T、Gruenwald J、Kligler B、Keifer D、Abrams TR、Woods J、Boon H、Kirkwood CD、Hackman DA、Basch E、Lafferty HJ;Natural Standard Research Collaboration Lemon balm(Melissa officinalis L):an evidence−based systematic review by the Natural Standard Research Collaboration J Herb Pharmacother 2005;5:71−114)、抗ウイルス)、抗菌及び抗酸化活性が報告されてきた(Bolkent S、Yanardag R、Karabulut−Bulan O、Yesilyaprak B Protective role of Melissa officinalis L extract on liver of hyperlipidemic rats:a morphological and biochemical study J Ethnopharmacol 2005;99:391−8、Ali Zarei1, Saeed Changizi Ashtiyani, Soheila Taheri, Fateme Rasekh Comparison between effects of different doses ofofficinalisatorvastatin on the activity of liver enzymes in hypercholesterolemia rats AJP 2014;4(1)15−23)。レモンバーム抽出物は、Melissa officinalis leaf extractで、地中海沿岸及び中部に自生し、「メリッサ」とも呼ばれるハーブ植物として、レモンと類似した香が特徴であり、豊かなロスマリン酸成分を含有する。ロスマリン酸は、ダイエット、抗酸化、抗炎作用に役立つ。レモンバーム抽出物は、ポリフェノールとタンニン成分で皮膚の保護にも優れた効能を持つ。レモンバーム抽出物は、水、メタノール、エタノール及びこれらの中で2種以上の混合物からなる群より選択される極性溶媒、好ましくは水でレモンバーム全草、好ましくはレモンバームの葉を抽出して噴霧乾燥させて粉末化したものである。 Lemon balm (Melissa officinalis) is a plant belonging to the family Labiatae, and has a variety of active flavonoids (cinaroside, cosmosin, ramnocitrin and rhamnocitrin, isoquercitrin, isoquercitrin) It is known to contain (triterpene acids: ursolic acid and oleanolic acid) (Herodez SS, Hadolin M, Skerget M, Knez Z Solvent extremation study L) actives such as leaves Food Chemistry 200; 80: 275-82), essential oils, coffee acid and losolic acid, monoterpenes and sesquiterpenes, phenolic substances and tannins were also separated and extracted from lemon balm. To date, lemon balm extract antiseptic (Ulbricht C, Blender T, Grüenwald J, Kligler B, Keifer D, Abrams TR, Woods J, Boon H, Kirkwood balm (Melissa officinalis L): an evidence-based systematic review by the Natural Standard Research Collaboration J Herb Pharmacother R, Karabulut-Bulan O, Yesilyaprak B Protective role of Melissa officinalis L extract on liver of hyperlipidemic rats: a morphological and biochemical study J Ethnopharmacol 2005; 99: 391-8, Ali Zarei1, Saeed Changizi Ashtiyani, Soheila Taheri, Fateme Rasekh Comparison beween effects of different doses of officinal systematic review on the activity of liver enzymes in hypercholesterolemia rats AJP 2014; 4 (1). Lemon balm extract is a Melissa officinalis leaf extract that grows naturally on the Mediterranean coast and in the central part, and as an herbal plant also called "Melissa", it is characterized by a scent similar to lemon and contains a rich rosmarinic acid component. Rosmarinic acid helps with diet, antioxidant and anti-inflammatory effects. Lemon balm extract is a polyphenol and tannin component and has an excellent effect on skin protection. The lemon balm extract is prepared by extracting the whole lemon balm plant, preferably the leaves of lemon balm, with water, methanol, ethanol and a polar solvent selected from the group consisting of a mixture of two or more kinds thereof, preferably water, and spray-drying. It is powdered.
一名をマロニエ種子抽出物と呼ばれるセイヨウトチノキ種子抽出物(AESCULUS HIPPOCASTANUM(HORSE CHESTNUT) SEED EXTRAC)は、抗浮腫作用、抗炎症作用、血管組織壁に対して浮腫形成の防止、給薬性の減少だけでなく、皮膚を紫外線から守って肝斑を予防し、荒い皮膚を防止する効果がある。 Horse chestnut seed extract (AESCULUS HIPPOCASTANUM (HORSE CHESTNUT) SEED EXTRAC), one of which is called horse chestnut seed extract, has anti-edema effect, anti-inflammatory effect, prevention of edema formation on vascular tissue wall, and reduction of drug feeding property. Not only that, it protects the skin from ultraviolet rays, prevents liver spots, and has the effect of preventing rough skin.
クルミ抽出物(JUGLANS REGIA (WALNUT) SEED EXTRACT)は、細胞で角質形成細胞による角質層の分化を促進し、損傷された皮膚の障壁機能を回復させ、保湿力の増加及び維持に優れた効果があるだけでなく、肥満細胞における脱料粒阻害及び免疫細胞の増殖効果に優れ、抗炎、刺激緩和の効果がある。 Walnut extract (JUGLANS REGIA (WARNUT) SEED EXTRACT) promotes the differentiation of the stratum corneum by keratinogenic cells in cells, restores the barrier function of damaged skin, and has an excellent effect on increasing and maintaining moisturizing power. Not only that, it is excellent in inhibiting keratinocytes in mast cells and proliferating immune cells, and has anti-inflammatory and stimulating alleviating effects.
ヒバマタ抽出物は、大きな褐藻類海草から抽出した成分であり、多量のミネラル、ビタミン、アミノ酸を含有し、皮膚を保護し、水和して荒くて乾燥した皮膚をしっとりとする効果がある。脂肪を吸収し、老廃物の排出に役立つ。 Rockweed extract is a component extracted from large brown algae seaweed, contains a large amount of minerals, vitamins and amino acids, and has the effect of protecting the skin and moisturizing rough and dry skin. Absorbs fat and helps eliminate waste products.
塩化ナトリウム(SODIUM CHLORIDE)は、ソジウム(ナトリウム)とクロライド(塩化物)の化合物である無機塩成分であり、化粧品及び美容製品で酸度調節剤、防腐機能、香味剤、粘度増進剤として使用される。 Sodium chloride (SODIUM CHLORIDE) is an inorganic salt component that is a compound of sodium (sodium) and chloride (chloride), and is used as an acidity adjuster, antiseptic function, flavoring agent, and viscosity enhancer in cosmetics and beauty products. ..
プロピレングリコール(PROPYLENE GLYCOL)は、プロピレンオキシドを加水分解させて得られる成分であり、分子量が小さくて皮膚浸透力に優れ、有効成分を浸透させるための用途として使用される。皮膚中の水分を維持させて皮膚保湿力を向上させる効果がある。 Propylene glycol (PROPYLENE GLYCOL) is a component obtained by hydrolyzing propylene oxide, has a small molecular weight, has excellent skin penetrating power, and is used for permeating an active ingredient. It has the effect of maintaining the moisture in the skin and improving the moisturizing power of the skin.
フェノキシエタノール(PHENOXYETHANOL)は、フェノールとエチレングリコールが結合した成分であり、主に化粧品に防腐剤と保留剤の役割をする成分であり、ひと時乳房癌で悪名をはせたパラベンの代わりに化粧品に使用される代替防腐剤の一つである。 Phenoxyethanol (PHENOXYETHANOL) is a component in which phenol and ethylene glycol are combined, and is a component that mainly acts as a preservative and a fixative in cosmetics, and is used in cosmetics instead of paraben, which was once notorious for breast cancer. It is one of the alternative preservatives to be used.
メチルプロパンジオールは、溶媒で使用されるグリコールの一種である。各種の成分(サリチル酸など)が皮膚に浸透するように役立つ。水和(Hydrating)属性があり、皮膚を柔らかくしっとりとするのに役立つ。 Methylpropanediol is a type of glycol used in solvents. Helps various ingredients (such as salicylic acid) penetrate the skin. It has a hydrating attribute and helps to soften and moisturize the skin.
チロシンは、メラニンの生成を始める皮膚アミノ酸である。体内カテコールアミン(Catecholamine)、甲状腺ホルモンであるチロキシン(Thyroxine)の前駆体として、脂肪代謝を促進する。 Tyrosine is a skin amino acid that initiates the production of melanin. It promotes lipid metabolism as a precursor of catecholamines in the body and thyroxine, which is a thyroid hormone.
エチルヘキシルグリセリン(ETHYLHEXYLGLYCERIN)は、グリセリルエーテルとして有機化合物成分であり、グリセリンの一種類として柔らかさ、湿潤剤及び適正な滲み性能を持った湿潤剤の一種である。フェノキシエタノール、イソチアゾリノン、そしてパラベンなどのような防腐剤の抗菌力を増加させて防腐剤の使用量を減らすことができる。バクテリア成長を抑制して脱臭効果があり、皮膚コンディショニングを付与する。 Ethylhexyl glycerin (ETHYLHEXYLGLYCERIN) is an organic compound component as glyceryl ether, and is a kind of wetting agent having softness, wetting agent and appropriate bleeding performance as one kind of glycerin. The antibacterial activity of preservatives such as phenoxyethanol, isothiazolinone, and parabens can be increased to reduce the amount of preservatives used. It suppresses bacterial growth, has a deodorizing effect, and imparts skin conditioning.
メチルシラノールマンヌロン酸(METHYLSILANOL MANNURONATE)は、有機シリコーンOrganic silicon(SI)であるシラノール(Silanol)と褐藻類のアルギン酸に由来したマンヌロン酸(Mannuronic Acid)が結合した物質であり、皮膚再生、弾力強化、線状皮膚萎縮症の防止効果及び抗酸化、脂肪分解、保湿効果などがある。 Methylsilanol mannuronic acid (METHYLSILANOL MANNURONATE) is a substance in which silanol, which is an organic silicone organic silicon (SI), and mannuronic acid, which is derived from alginic acid of brown algae, are bound to each other, and has skin regeneration and elasticity. It strengthens, prevents linear skin atrophy, and has antioxidant, lipolytic, and moisturizing effects.
ソルビン酸(SORBIC ACID)は、ブルーベリーのようなベリー類に存在する成分であり、細菌、カビなどの微生物の生育抑制効果があり、全ての化粧品に防腐成分として主に使用される。化粧品だけでなく食品にも許容される成分である。 Sorbic acid (SORBIC ACID) is a component present in berries such as blueberries, has an effect of suppressing the growth of microorganisms such as bacteria and molds, and is mainly used as an antiseptic component in all cosmetics. It is an ingredient that is acceptable not only for cosmetics but also for foods.
アデノシンリン酸は、複合性、しわ改善、抗炎剤、鎮静剤、細胞対話成分であり、真皮層内の皮膚細胞活性化酸素を伝達して繊維芽細胞の大きさの増大及び増殖を強化してコラーゲン合成を促進する。 Adenosine phosphate is a complex, wrinkle-improving, anti-inflammatory, sedative, and cell-interactive component that transmits skin cell-activating oxygen within the dermis to enhance fibroblast size growth and proliferation. Promotes collagen synthesis.
アデノシン三リン酸二ナトリウムは、アデノシン三リン酸のジナトリウム塩成分である。皮膚にコンディショニングを付与する役割として使用される。 Adenosine triphosphate disodium is a disodium salt component of adenosine triphosphate. It is used to give conditioning to the skin.
頬骨が発達して印象が強く見える場合、年を取りながらあご脂肪(jowl fat)、あご線などが垂れた場合、豊麗線横の頬のため豊麗線が深く見える場合、頬や二重あごのように部分的に脂肪が多い場合、ボトックスだけでは四角あごの校正にならない場合、輪郭や顎削り手術をしたにも顔ラインが校正にならなかった場合、脂肪吸入や手術を恐れる場合、脂肪移植が過度な場合、リフティングの前/後、顔面非対称患者、既存の脂肪分解薬物で効果を見られなかった場合、短い時間に日常生活に差し支えなく細長い顔を望む患者を対象とする。 If the cheekbones develop and the impression looks strong, if the chin fat (jowl fat), chin line, etc. hang down as you get older, if the cheeks next to the chin line make the chin line look deeper, if the cheeks or double chin If you have a lot of fat, if Botox alone does not calibrate your square chin, if your face line does not calibrate even after contouring or chin-shaving surgery, if you are afraid of fat inhalation or surgery, fat transplantation It is intended for patients with facial asymmetry before / after lifting, patients who desire an elongated face in a short period of time without any problem in daily life, if the existing lipolytic drugs are not effective.
注射剤投薬の臨床結果は、次の通りである。 The clinical results of injectable dosing are as follows.
患者年齢は20代以上の男女患者を対象とする。毎週1回ずつ、4回を一ヶ月間施術した後の結果である。施術方法は30〜40分軟膏で痲酔した後、32G needle(1cc syringe)、Mesogunを使用した。レモンバーム組成物Solutionは、1cc当たり3−4pointに分けて皮下(SQ level)に注射する。施術後、柔らかくマッサージをして、抗生剤軟膏またはVit.K軟膏を塗布する。 The patient age is for male and female patients in their twenties and over. This is the result after performing 4 times for 1 month, once a week. As a treatment method, after being intoxicated with an ointment for 30 to 40 minutes, 32G needle (1cc syringe) and Mesogun were used. Lemon balm composition Solution is injected subcutaneously (SQ level) in 3-4 points per cc. After the treatment, massage softly with antibiotic ointment or Vit. Apply K ointment.
次の表2は、施術部位別の施術回数、用量及び間隔を示した表である。 The following Table 2 is a table showing the number of treatments, the dose, and the interval for each treatment site.
図2及び3は、本発明の実施例による組成物が脂肪細胞に反応した実験を示した電子顕微鏡写真を示す。図2は、組成物の投入前の写真であり、図3は、組成物の投入後の写真である。赤色の丸が脂肪細胞を示し、約80%の脂肪細胞が減少したことを確認することができる。 FIGS. 2 and 3 show electron micrographs showing an experiment in which the composition according to the embodiment of the present invention reacted with adipocytes. FIG. 2 is a photograph before the addition of the composition, and FIG. 3 is a photograph after the addition of the composition. The red circles indicate adipocytes, and it can be confirmed that about 80% of adipocytes are reduced.
図4及び5は、本発明の実施例による注射剤組成物を利用した施術を4週間行う前と行った後の写真をそれぞれ示す。図示のように、4週ぶりに脂肪及びセルライトの分解によりドラマチックな顔ラインの変化を確認することができる。 FIGS. 4 and 5 show photographs before and after the treatment using the injectable composition according to the embodiment of the present invention for 4 weeks, respectively. As shown in the figure, dramatic changes in the facial line can be confirmed by decomposition of fat and cellulite for the first time in 4 weeks.
一方、本発明の第2実施例によるレモンバーム抽出物を有効成分として含む化粧料組成物を以下で説明する。 On the other hand, the cosmetic composition containing the lemon balm extract according to the second embodiment of the present invention as an active ingredient will be described below.
本発明の実施例によるレモンバーム抽出物を有効成分として含む脂肪分解用化粧料組成物は、脂肪分解、リンパ循環、Vライン顔、弾力のある顔のために化粧料組成物として塗布されることができる。 The lipolytic cosmetic composition containing the lemon balm extract according to the embodiment of the present invention as an active ingredient may be applied as a cosmetic composition for lipolysis, lymphatic circulation, V-line face, and elastic face. can.
本発明の実施例による脂肪分解組成物は、レモンバーム抽出物、マロニエ(Aesculus Hippocastanum)抽出物、ヒバマタ抽出物、クルミ抽出物、ADP(Disodium Adenosine Phosphate)、Adenosine Triphosphate、Tyrosineを含むことが好ましい。 The lipolytic composition according to the examples of the present invention preferably contains lemon balm extract, horse chestnut (Aesculus Hippocastanum) extract, hibamata extract, walnut extract, ADP (Disodium Adenosine Phosphate), and Adenosine Triphosphate.
本発明の第2実施例による脂肪分解用化粧料組成物は、次の成分で構成されることが好ましい。 The lipolytic cosmetic composition according to the second embodiment of the present invention is preferably composed of the following components.
第1実施例と同一成分の効能に対する説明は省略する。 The description of the efficacy of the same ingredient as in the first embodiment will be omitted.
レモンバーム抽出物は、水、メタノール、エタノール及びこれらの中で2種以上の混合物からなる群より選択される極性溶媒、好ましくは水でレモンバーム全草、好ましくはレモンバームの葉を抽出して噴霧乾燥させて粉末化したものである。本実施例では、レモンバーム抽出物の皮膚適用時に脂肪及びセルライトの減少効果を利用した。 The lemon balm extract is prepared by extracting the whole lemon balm plant, preferably the leaves of lemon balm, with water, methanol, ethanol and a polar solvent selected from the group consisting of a mixture of two or more kinds thereof, preferably water, and spray-drying. It is powdered. In this example, the effect of reducing fat and cellulite was utilized when the lemon balm extract was applied to the skin.
上記組成物を利用して2019年1月から3月まで100人の非施術者を対象として臨床を実施した。 Using the above composition, clinical practice was performed on 100 non-operators from January to March 2019.
非施術者は、次の表4のように非施術者のセルライト種類に分類された。 Non-practitioners were classified into non-practitioner cellulite types as shown in Table 4 below.
転子周囲(peritrochanteric)と膝の内側を含む施術該当部位の全体にエレクトロポレーション(electroporation)を適用し、次のような結果を得た。電気穿孔法という意味のエレクトロポレーション(electroporation)は、皮膚脂質に電気パルスを加えて一時的に皮膚脂質を開くため、本発明の実施例による組成物のようなフォーミュラ吸収により効果的である。 Electroporation was applied to the entire area of the operation, including the peritrochanteric area and the inside of the knee, and the following results were obtained. Electroporation, which means electroporation, is more effective at formula absorption, such as the composition according to the embodiments of the present invention, because it applies an electrical pulse to the skin lipids to temporarily open the skin lipids.
臨床は、毎週1回ずつ非施術者の状態によって4〜10週間にわたって進行された。その後は一週間おきに1回、総2回を進行し、2回実施後は「維持の目的」で一月に1回のみ進行した。1回当り時間は最小30分から最大40分であり、パワーレベルは75〜90%であった。適用部位に柔らかく円を描くようにマッサージをするという点に注意する。「維持の目的」の施術を除いて、総5〜10回の施術を受けた非施術者は、全体の71%であり、「維持の目的」施術を含み11〜20回を受けた非施術者が25%、21回以上を受けた非施術者が4%であった。 The clinic progressed once a week for 4-10 weeks depending on the condition of the non-practitioner. After that, it progressed once every other week, a total of two times, and after the two times, it progressed only once a month for the purpose of "maintenance". The time per session was from a minimum of 30 minutes to a maximum of 40 minutes, and the power level was 75 to 90%. Note that the massage is done in a soft circle on the application site. Excluding the "maintenance purpose" treatment, 71% of the non-practitioners received a total of 5 to 10 treatments, and 11 to 20 non-treatments including the "maintenance purpose" treatment. 25% of the patients and 4% of the non-operators received 21 times or more.
体重減量の変化は次の表7の通りである。 The changes in weight loss are shown in Table 7 below.
図7は、非施術者の総合評価を示した表である。施術に対する非施術者の主観的な評価が行われ、評価基準は体重の変化だけでなく、施術過程で表れることができる症侯群(副作用)の程度と日常生活への速い復帰なども含まれている。 FIG. 7 is a table showing the comprehensive evaluation of non-practitioners. A non-practitioner's subjective evaluation of the treatment is performed, and the evaluation criteria include not only changes in body weight, but also the degree of symptom group (side effects) that can appear during the treatment process and quick return to daily life. ing.
3%の非施術者から両太股における一般的な血管拡張が観察された。これは一過性(transient)で痛症はなく、迷走神経(vagal)による症状ではなかった。下方の太股部分が薄暗く赤くなってから消える現象であり、同種の療法製品に対する反応程度であると理解される。 General vasodilation in both thighs was observed in 3% of non-operators. It was transient, painless, and not a vagal symptom. It is a phenomenon in which the lower thigh part becomes dim and red and then disappears, and it is understood that it is only a reaction to the same type of therapeutic product.
注目に値する事実は、臨床に参加した非施術者の中で、一人も耐性が生じず同種の療法に対する拒否反応も表れなかったということである。非施術者の製品に対する受容(acceptance)が非常に優れ、かゆみ証、腫れ上がり、アレルギー現象、苦痛、深刻な紅斑などは全くなかった。 A notable fact is that none of the non-practitioners who participated in the clinic developed resistance and did not show rejection of the same type of therapy. The non-practitioner's acceptance of the product was very good, with no itchiness, swelling, allergic phenomena, distress, or severe erythema.
図8は、29歳女性の施術の前(a)と後(b)の写真である。一週間に1回ずつ6回施術した結果である。 FIG. 8 is a photograph of a 29-year-old woman before (a) and after (b) the treatment. This is the result of 6 treatments, once a week.
図9は、43歳女性の施術の前(a)と後(b)の写真である。一週間に1回ずつ10回施術した結果である。
図示のように、施術部位の脂肪及びセルライトの分解によりドラマチックな変化を確認することができる。
FIG. 9 is a photograph of a 43-year-old woman before (a) and after (b) the treatment. This is the result of 10 treatments once a week.
As shown, dramatic changes can be confirmed by the decomposition of fat and cellulite at the treatment site.
Claims (1)
レモンバーム抽出物、塩化ナトリウム、ヒバマタ抽出物、セイヨウトチノキ種子抽出物、クルミ(JuglansRegia)抽出物、チロシン、アデノシン三リン酸二ナトリウム、アデノシンリン酸、メチルプロパンジオール、メチルシラノールマンヌロン酸を含み、
前記組成物は、超音波機器、高周波機器、エレクトロポレーション、または針のないインジェクトによって皮膚に適用され、
前記組成物は、
塩化ナトリウム0.898重量%、レモンバーム抽出物0.01875重量%、チロシン0.00800重量%、セイヨウトチノキ種子抽出物0.00560重量%、クルミ抽出物0.00560重量%、ヒバマタ抽出物0.00240重量%、アデノシンリン酸0.00024重量%、アデノシン三リン酸二ナトリウム0.00024重量%、メチルプロパンジオール0.04000重量%、メチルシラノールマンヌロン酸0.00180重量%及び残量の精製水を含むことを特徴とするレモンバーム抽出物を有効成分とする化粧料組成物。
The lemon balm extract a cosmetic composition comprising, as an active ingredient,
Contains lemon balm extract, sodium chloride, hibamata extract, horse chestnut seed extract, walnut (JuglansRegia) extract, tyrosine, disodium adenosine triphosphate, adenosine phosphate, methylpropanediol, methylsilanol mannuronic acid,
The composition, ultrasound equipment, high-frequency equipment, applied to the skin by electroporation or without needle injected,
The composition is
Sodium chloride 0.898% by weight, lemon balm extract 0.01875% by weight, tyrosine 0.00800% by weight, green beetle seed extract 0.00560% by weight, walnut extract 0.00560% by weight, hibamata extract 0.00240% by weight %% by weight, 0.00024% by weight of adenosine phosphate, 0.00024% by weight of disodium adenosine triphosphate, 0.04000% by weight of methylpropanediol, 0.00180% by weight of methylsilanol mannuronic acid, and purified water remaining. cosmetic composition comprising, as an active ingredient, lemon balm extract, which comprises a.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190033690A KR102036186B1 (en) | 2019-03-25 | 2019-03-25 | Composition comprising lemon balm extract for lipolysis |
KR10-2019-0033690 | 2019-03-25 | ||
KR10-2019-0050030 | 2019-04-29 | ||
KR1020190050030A KR102027827B1 (en) | 2019-04-29 | 2019-04-29 | Composition comprising lemon balm extract for lipolysis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020158484A JP2020158484A (en) | 2020-10-01 |
JP6943941B2 true JP6943941B2 (en) | 2021-10-06 |
Family
ID=72611582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019234300A Active JP6943941B2 (en) | 2019-03-25 | 2019-12-25 | Injectable and cosmetic compositions containing lemon balm extract as an active ingredient |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6943941B2 (en) |
CN (1) | CN111728903B (en) |
WO (1) | WO2020197041A1 (en) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100645385B1 (en) * | 2005-10-05 | 2006-11-23 | 주식회사 안지오랩 | Obesity Inhibitory Composition |
JP5081203B2 (en) * | 2003-07-29 | 2012-11-28 | 花王株式会社 | Lipolysis accelerator |
JP2007091645A (en) * | 2005-09-29 | 2007-04-12 | Ichimaru Pharcos Co Ltd | Food/drink for antiobese use containing melia azadirachta l. extract |
JP2008074814A (en) * | 2006-09-25 | 2008-04-03 | Nivea Kao Kk | Lipolysis promoter |
RS20100392A3 (en) * | 2010-09-06 | 2012-12-31 | Pavlov, Aleksandar | Procedure for obtaining herbal preparation based on herbal mixture extract for application on skin and herbal preparation obtained thereof |
KR20120086436A (en) * | 2011-01-26 | 2012-08-03 | 주식회사 코스메카코리아 | Cosmetic composition for slimming |
CN107149588A (en) * | 2012-01-23 | 2017-09-12 | 雷斯托尔西有限公司 | Cosmetic composition |
CN107149582A (en) * | 2017-05-13 | 2017-09-12 | 佛山文森特知识产权服务有限公司 | A kind of anti-apolexis composition and its application |
KR101825171B1 (en) * | 2017-07-31 | 2018-02-02 | 이충녕 | Composition for improving skin elasticity and female breast expansion |
CN108125892A (en) * | 2017-12-11 | 2018-06-08 | 百朗德生物化学(海门)有限公司 | A kind of marine organism moisture-retention anti-aging cosmetics composition |
CN108309834A (en) * | 2018-04-19 | 2018-07-24 | 广州赛莱拉干细胞科技股份有限公司 | Skin care compositions based on brown alga extract |
CN109464452A (en) * | 2018-12-28 | 2019-03-15 | 广州涵夏基因健康科技有限公司 | Application of the adenosine triphosphate salt in preparation external application fat-eliminating slimming product |
KR102027827B1 (en) * | 2019-04-29 | 2019-10-02 | 임재선 | Composition comprising lemon balm extract for lipolysis |
KR102036186B1 (en) * | 2019-03-25 | 2019-10-24 | 임재선 | Composition comprising lemon balm extract for lipolysis |
-
2019
- 2019-12-04 WO PCT/KR2019/017047 patent/WO2020197041A1/en active Application Filing
- 2019-12-25 JP JP2019234300A patent/JP6943941B2/en active Active
-
2020
- 2020-01-10 CN CN202010024143.1A patent/CN111728903B/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2020197041A1 (en) | 2020-10-01 |
CN111728903A (en) | 2020-10-02 |
CN111728903B (en) | 2022-11-01 |
JP2020158484A (en) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3466447B1 (en) | Pharmaceutical composition for treating multiple forms of skin wounds and manufacturing method thereof | |
CN103479775B (en) | Scraping liniment and preparation method thereof | |
CN106074206B (en) | A kind of skin care host agent, preparation method and applications | |
CN108452275A (en) | It is a kind of to have effects that the composition, medicament and preparation method of relaxing tendons and activating collaterals | |
KR102027827B1 (en) | Composition comprising lemon balm extract for lipolysis | |
RU2314093C2 (en) | Curative-cosmetic agent | |
CN105250606A (en) | Natural plant acne removing agent | |
JP6943941B2 (en) | Injectable and cosmetic compositions containing lemon balm extract as an active ingredient | |
US20160106798A1 (en) | Topical treatment for use in conjunction with acupuncture or acupressure therapy | |
US9421235B2 (en) | Medicine containing extracts of Ficus microcarpa for healing wounds of a diabetic patient | |
KR102036186B1 (en) | Composition comprising lemon balm extract for lipolysis | |
CN107441340B (en) | Hand and foot chap cream for relieving swelling, pain and itching and nourishing skin and preparation method thereof | |
CN106924134A (en) | A kind of Chinese medicine whitening spot-relieving cream and preparation method thereof | |
WO2001064229A1 (en) | A medicine for treating obesity and the method of producing thereof | |
KR101611966B1 (en) | Production of antlers and medicinal herbs extract for arthritis care medicine | |
CN110812377B (en) | Acne treatment and repair composition and application thereof | |
CN106727051A (en) | A kind of Chinese medicine anti-acne elite and preparation method thereof | |
CA2620242A1 (en) | Topical soothing bruise healing preparation | |
CN106038399B (en) | A kind of foot film and preparation method thereof of the anti-chap deodorization of anti-inflammatory | |
KR102576331B1 (en) | Injection composition for local fat removal and operating method thereof | |
CN110269926A (en) | Middle benefit gas, which is relaxed, warms up composition and its preparation method and application | |
CN110856708A (en) | Facial mask liquid and preparation method thereof | |
KR101930039B1 (en) | Composition for treatment of dermal diseases caused by human papilloma viruses | |
RU2308962C1 (en) | Agent for treatment and prophylaxis of locomotor system diseases | |
CN119367500A (en) | A Chinese medicine composition for hair growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201222 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210319 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210621 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210824 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210909 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6943941 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |